Arrowstreet Capital
SUPN icon

Arrowstreet Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Arrowstreet Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
71,393
+63,798
+840% +$3.06M ﹤0.01% 1412
2026
Q1 		$393K Sell
7,595
-176,093
-96% -$8.97M ﹤0.01% 1703
2025
Q4 		$9.13M Sell
183,688
-42,722
-19% -$2.08M 0.01% 953
2025
Q3 		$10.8M Sell
226,410
-21,567
-9% -$869K 0.01% 936
2025
Q2 		$7.82M Sell
247,977
-8,429
-3% -$270K 0.01% 989
2025
Q1 		$8.4M Buy
256,406
+81,490
+47% +$2.89M 0.01% 861
2024
Q4 		$6.32M Buy
174,916
+77,393
+79% +$2.73M 0.01% 944
2024
Q3 		$3.04M Buy
+97,523
New +$3.04M ﹤0.01% 1121
2023
Q1 		– Sell
-39,105
Closed -$1.4M – 1517
2022
Q4 		$1.4M Buy
39,105
+30,061
+332% +$1.04M ﹤0.01% 955
2022
Q3 		$306K Buy
+9,044
New +$294K ﹤0.01% 1161
2020
Q4 		– Sell
-179,631
Closed -$3.74M – 2528
2020
Q3 		$3.74M Buy
179,631
+22,313
+14% +$506K 0.01% 1290
2020
Q2 		$3.74M Buy
157,318
+129,018
+456% +$2.85M 0.01% 1183
2020
Q1 		$509K Sell
28,300
-23,481
-45% -$493K ﹤0.01% 1525
2019
Q4 		$1.23M Buy
+51,781
New +$1.26M ﹤0.01% 1286
2019
Q2 		– Sell
-35,836
Closed -$1.26M – 1685
2019
Q1 		$1.26M Buy
+35,836
New +$1.33M ﹤0.01% 1258
2016
Q4 		– Sell
-9,667
Closed -$239K – 2428
2016
Q3 		$239K Buy
+9,667
New +$219K ﹤0.01% 1390
2016
Q1 		– Sell
-70,600
Closed -$949K – 1515
2015
Q4 		$949K Buy
+70,600
New +$1.09M ﹤0.01% 1003

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Arrowstreet Capital's SUPN Position: Q2 2026 in Review

Arrowstreet Capital increased its Supernus Pharmaceuticals (SUPN) stake by 840% in Q2 2026, buying an estimated $3.06M and bringing the position to 71,393 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Arrowstreet Capital first reported a position in SUPN in Q4 2015 and has held it in 17 quarters since. The position peaked at $10.8M in Q3 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Arrowstreet Capital held 71,393 shares of Supernus Pharmaceuticals worth $3.32M as of Q2 2026.
  • Arrowstreet Capital bought 63,798 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.06M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1412 holding.
  • Arrowstreet Capital first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 17 quarters since.
  • Arrowstreet Capital's Supernus Pharmaceuticals position peaked at $10.8M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.